<SEC-DOCUMENT>0001493152-22-034062.txt : 20221201
<SEC-HEADER>0001493152-22-034062.hdr.sgml : 20221201
<ACCEPTANCE-DATETIME>20221201060648
ACCESSION NUMBER:		0001493152-22-034062
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221129
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221201
DATE AS OF CHANGE:		20221201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NanoVibronix, Inc.
		CENTRAL INDEX KEY:			0001326706
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36445
		FILM NUMBER:		221437211

	BUSINESS ADDRESS:	
		STREET 1:		525 EXECUTIVE BLVD
		CITY:			ELMSFORD
		STATE:			NY
		ZIP:			10523
		BUSINESS PHONE:		(914) 233-3004

	MAIL ADDRESS:	
		STREET 1:		525 EXECUTIVE BLVD
		CITY:			ELMSFORD
		STATE:			NY
		ZIP:			10523

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix, Inc.
		DATE OF NAME CHANGE:	20111206

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix Inc
		DATE OF NAME CHANGE:	20050510
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:NAOV="http://nanovibronix.com/20221129">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_NAOV_nanovibronix.com_20221129 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20221129_20221129 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001326706 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityCentralIndexKey">0001326706</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="naov-20221129.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-29to2022-11-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-29</xbrli:startDate>
        <xbrli:endDate>2022-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20221129__20221129_zwZnaMkb4q9g"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20221129__20221129_zl4Yyllt2X2d"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 29, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20221129__20221129_zOpXia0RukF4"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityRegistrantName">NanoVibronix,
Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20221129__20221129_zulxho2MAbF9"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
or other jurisdiction of incorporation)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20221129__20221129_zrMRdyLknbw6"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityFileNumber">001-36445</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20221129__20221129_zfqtL1MRulLi"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityTaxIdentificationNumber">01-0801232</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission <br />
    File Number)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS Employer <br />
    Identification No.) </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityAddressAddressLine1_c20221129__20221129_zrFLzgwWsgP"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityAddressAddressLine1">525
Executive Blvd.</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20221129__20221129_zg5gg9P95Wui"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityAddressCityOrTown">Elmsford</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20221129__20221129_zE2SwctIZxr6"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20221129__20221129_zuFqiq5L30S8"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityAddressPostalZipCode">10523</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90D_edei--CityAreaCode_c20221129__20221129_zxopAQTCqPrf"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:CityAreaCode">(914)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20221129__20221129_zSxAvqD9Okmi"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:LocalPhoneNumber">233-3004</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityInformationFormerLegalOrRegisteredName_c20221129__20221129_zbe6DoeyQiu1"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:EntityInformationFormerLegalOrRegisteredName">Not
Applicable</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--WrittenCommunications_c20221129__20221129_zJz6oKqrFB5f"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20221129__20221129_zWqXEQtLaUZ2"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20221129__20221129_zESV0qlaPnej"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20221129__20221129_zAMYZlzkpm2c"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20221129__20221129_zl3kZvur932l"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20221129__20221129_z0MUw2FpDEq9"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:Security12bTitle">Common Stock, par value
    $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20221129__20221129_zkhhJrdhsIFh"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" name="dei:TradingSymbol">NAOV</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_905_edei--SecurityExchangeName_c20221129__20221129_zoHx1jfAkrXj"><ix:nonNumeric contextRef="From2022-11-29to2022-11-29" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01 Entry into
    a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2022, NanoVibronix, Inc. (the &#8220;<b><i>Company</i></b>&#8221;) entered into a securities purchase agreement (the &#8220;<b><i>Purchase
Agreement</i></b>&#8221;) with certain institutional investors (the &#8220;<b><i>Purchasers</i></b>&#8221;), pursuant to which the Company
agreed to sell to the Purchasers in a registered direct offering (the &#8220;<b><i>Offering</i></b>&#8221;) 4,800,000 shares (the &#8220;<b><i>Shares</i></b>&#8221;)
of the Company&#8217;s common stock, $0.00001 par value per share (the &#8220;<b><i>Common Stock</i></b>&#8221;), at an offering price
of $0.50 per share of Common Stock. The Offering is expected to close on or about December 1, 2022, subject to satisfaction of customary
closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to receive net proceeds from the sale of the Shares, after deducting placement agent fees and other estimated offering
expenses payable by the Company, of approximately $2.1 million. The Company intends to use the net proceeds for general working capital
purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2022, the Company entered into an engagement letter (the &#8220;<b><i>Engagement Letter</i></b>&#8221;) with H.C. Wainwright
&amp; Co., LLC (the &#8220;<b><i>Wainwright</i></b>&#8221;), pursuant to which Wainwright agreed to serve as the exclusive placement
agent for the Company, on a reasonable best-efforts basis, in connection with the Offering. The Company will pay Wainwright an aggregate
cash fee equal to 7.5% of the gross proceeds of the Offering, a management fee equal to 1.0% of the gross proceeds of the Offering, a
non-accountable expense allowance of $50,000 and $15,950 for clearing fees. Additionally, the Company has agreed to issue to Wainwright
or its designees as compensation, warrants to purchase up to 360,000 shares of Common Stock, equal to 7.5% of the aggregate number of
Shares placed in the Offering (the &#8220;<b><i>Placement Agent Warrants</i></b>&#8221;). The Placement Agent Warrants have a term of
five (5) years from the commencement of sales under the Offering and an exercise price of $0.625 per share of Common Stock (equal to
125% of the offering price per share of Common Stock).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
of the Placement Agent Warrants nor the shares of Common Stock issuable upon the exercise of the Placement Agent Warrants (the &#8220;<b><i>Placement
Agent Warrant Shares</i></b>&#8221;) are registered under the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;).
The Placement Agent Warrants and the Placement Agent Warrant Shares will be issued in reliance on the exemptions from registration provided
by Section 4(a)(2) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of the Shares will be made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 (Registration No. 333-239965),
including a prospectus contained therein dated August 11, 2020, as supplemented by a prospectus supplement, dated November 29, 2022,
relating to the Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement contains customary representations, warranties, and covenants of the Company and also provides for customary indemnification
by the Company against certain liabilities of the Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1
hereto. The foregoing descriptions of the terms and conditions of the Purchase Agreement and the Placement Agent Warrants do not purport
to be complete and are qualified in their entirety by the full text of the form of the Purchase Agreement and the form of the Placement
Agent Warrant, copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 3.02</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
                                            Sales of Equity Securities.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in Item 1.01 of this Current Report on Form 8-K in relation to the Placement Agent Warrants and the Placement Agent
Warrant Shares is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
                                            Events.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2022, the Company issued a press release regarding the Offering described above under Item 1.01 of this Current Report on
Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Placement Agent Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Haynes and Boone, LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Haynes and Boone, LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release, dated November 29, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 1, 2022</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">NANOVIBRONIX,
    Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Stephen
    Brown</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Brown</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OXI18sHHpCKyCJHodckplnRHZlerT+ovW5VoGBiGe8+9QszElja6RobLqsihxKatlUMo8IaM5oreke32Kfhb4F1bx8q48f2BGXkGPbOcR8nVC6O11xarFKIoXMgwjkEmqVzA6SCCQc/I3HSFxmlVgzIVnJha1ugUv6eEUr3IUPMeq87IVpPxcXM5yR+IZRTDkXr1JH5YyPNMBLNxArFl6tqhprOOGljX2PguO6H/Db4XAUlH -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NanoVibronix,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares:
  _______</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue Date: December
  1, 2022</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: December
  1, 2022</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior
to 5:00 p.m. (New York City time) on November 29, 2027 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for
and purchase from NanoVibronix, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement,
by and between H.C. Wainwright &amp; Co., LLC and the Company, dated as of October 6, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated November 29, 2022, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.625</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
(&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exercise Price of this
Warrant, as adjusted hereunder; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this
Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise (provided that delivery of the aggregate Exercise
Price is made by such date), (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (provided that
delivery of the aggregate Exercise Price is made by such date) (such earliest date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share
Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the
Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of
this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)
the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or
more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of
the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the
Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume
all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity
or Successor Entities, jointly and severally, had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, to provide to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company to the effect that the transfer of this Warrant does not require registration under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict
of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant
shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;).
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York
Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an
action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be
reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at the address set forth above Attention: Chief Executive Officer, email address bmurphy@nanovibronix.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email, or
sent by a nationally recognized overnight courier service addressed to each Holder at the email address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the date of transmission, if such notice or communication is delivered via email at the email address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via email at the email address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NanoVibronix,
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To: <B>NanoVibronix,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: _______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
Print)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Phone
    Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Email
    Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    <B>_______________ __, ______</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: <B>___________________</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT> <B>____________________</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
1, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">525
Executive Blvd.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elmsford,
NY 10523</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Statement on Form S-3, Registration No. 333-239965</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to NanoVibronix, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the
preparation and filing with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) pursuant to Rule 424(b)
under the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;) of the Company&rsquo;s prospectus supplement, dated
November 29, 2022 (the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;), forming part of the registration statement on Form S-3, Registration
No. 333-239965, initially filed by the Company with the Commission on July 21, 2020 as thereafter amended or supplemented, declared effective
on August 11, 2020 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;). The Prospectus Supplement relates to the proposed sale of
4,800,000 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B><I>Common
Stock</I></B>&rdquo;), pursuant to that certain Securities Purchase Agreement, dated November 29, 2022, by and among the Company and
the several institutional investors named therein (the &ldquo;<B><I>Securities Purchase Agreement</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinion set forth herein, we have examined the originals, or photostatic or certified copies, of (i) the Certificate of
Incorporation and Bylaws of the Company, each as amended and/or restated as of the date hereof, (ii) certain resolutions of the Board
of Directors of the Company related to the filing of the Registration Statement and the Prospectus Supplement, the authorization and
issuance of the Shares and related matters, (iii) the Registration Statement and all exhibits thereto, (iv) the Prospectus Supplement
and the base prospectus, dated August 11, 2020, included in the Registration Statement (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;
and together with the Prospectus Supplement, the &ldquo;<B><I>Prospectus</I></B>&rdquo;), (v) the Securities Purchase Agreement, (vi)
the specimen Common Stock certificate, (vii) a certificate executed by an officer of the Company, dated as of the date hereof, and (viii)
such other records, documents and instruments as we deemed relevant and necessary for purposes of the opinion stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon such certificates of officers of the Company and of public officials and statements and information furnished by officers
of the Company with respect to the accuracy of material factual matters contained therein which were not independently established by
us. In such examination we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,
the conformity to original documents of all documents submitted to us as photostatic or certified copies, and the authenticity of the
originals of such copies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Haynes
and Boone, LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Attorneys
and Counselors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
Rockefeller Plaza, 26th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
212.659.7300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
212.918.8989</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making the foregoing examination we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity
of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as photostatic or
certified copies, and the authenticity of the originals of such copies. As to all questions of fact material to this opinion, where such
facts have not been independently established, we have relied, to the extent we have deemed reasonably appropriate, upon representations
or certificates of officers of the Company or governmental officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not considered, and express no opinion herein as to, the laws of any state or jurisdiction other than the General Corporation Law
of the State of Delaware, as currently in effect (the &ldquo;<B><I>DGCL</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that upon payment
and delivery in accordance with the Securities Purchase Agreement approved by the Board of Directors of the Company, the Shares will
be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K to be filed with the
Commission. We further consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus constituting
a part of the Registration Statement. In giving this consent, we are not admitting that we are within the category of persons whose consent
is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. This opinion is given as of the date
hereof and we assume no obligation to update or supplement such opinion after the date hereof to reflect any facts or circumstances that
may thereafter come to our attention or any changes that may thereafter occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Haynes and Boone, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HAYNES
    AND BOONE, LLP </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>
Exhibit 10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of November 29, 2022, between NanoVibronix, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its successors
and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<SUP>nd</SUP>)
Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Haynes and Boone, LLP, 30 Rockefeller Plaza, 26th Floor, New York, New York 10112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers, directors or consultants of the
Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to
the Company, provided that the aggregate number of shares of Common Stock issued to or issuable upon exercise of options issued to consultants
of the Company shall not exceed 100,000 shares, (b) warrants to the Placement Agent in connection with the transactions pursuant to this
Agreement, securities upon the exercise or exchange of or conversion of any Securities issued hereunder, and any securities upon exercise
of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein, and provided that
any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $0.50 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement and prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full,
in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement, including all information, documents and exhibits filed with or
incorporated by reference into such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act, including all information,
documents and exhibits filed with or incorporated by reference into such Prospectus Supplement, that is filed with the Commission and
delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-239965, including all information, documents
and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Shares and Pre-Funded
Warrants to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in; color: blue"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Pre-Funded Warrants purchased hereunder
as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, 18 Lafayette Place, Woodmere, New York 11598, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $2,400,000 of Shares. Notwithstanding anything herein
to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription Amount (together
with such Purchaser&rsquo;s Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s
Affiliates) would cause such Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership
Limitation, or as such Purchaser may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares
as determined pursuant to Section 2.2(a). The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election
of the Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of the Securities on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser.
Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available
for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to each Purchaser its
respective Shares and Pre-Funded Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver
the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Notwithstanding anything herein
to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through,
and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any
Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement
Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company),
be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares to such Purchaser at the Closing; provided, that the Company
shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase price
of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall
not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall
sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely
be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s)
of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which
may be delivered at any time after the time of execution of the this Agreement, the Company agrees to deliver the Pre-Funded Warrant
Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share
Delivery Date (as defined in the Pre-Funded Warrants) for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
to the difference between (A) such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price applicable to Pre-funded
Warrants and (B) the number of Shares otherwise issuable to such Purchaser that would cause such Purchaser&rsquo;s Beneficial Ownership
to be more than the Beneficial Ownership Limitation with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment
therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the
Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares and Pre-Funded Warrant Shares for trading thereon in the time and manner
required thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Pre-Funded Warrant Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued,
fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital
stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Pre-Funded Warrants. The Company has prepared
and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on August 11,
2020, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.
The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the
Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for
that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by
the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the
time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the
Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at
the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all
material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is
eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value
of securities being sold pursuant to this offering and during the twelve (12) calendar months prior to this offering, as set forth in
General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports, including the number
of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of
employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to
the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision
that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company
or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or
similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or
&ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the
Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state
securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for
the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect
to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the
Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports, (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through
the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository
Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes
or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. All outstanding secured and unsecured Indebtedness of the Company or
any Subsidiary, or for which the Company or any Subsidiary has commitments is set forth in the SEC Reports. For the purposes of this
Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other
than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<FONT STYLE="text-underline-style: double"><U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U></FONT>. Anything in this
Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged
by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from
purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued
by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this
or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii)
any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly,
presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities
are outstanding, including, without limitation, during the periods that the value of the Pre-Funded Warrant Shares deliverable with respect
to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that
such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. (i)(x) Since January 1, 2022, there has been no security breach or other compromise of or relating to any of the
Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including
the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment
or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified
of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise
to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and
all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and
contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data
from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems
and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Pre-Funded Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a) under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the earlier of the time that no Purchaser owns Securities, the Company covenants to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, agents, employees, Affiliates or agents, including,
without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition,
effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any
of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each
Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior
consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect
to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except
(a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables
in the ordinary course of the Company&rsquo;s business), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c)
for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct),
the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising
out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the
case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to
the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser
Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation
by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection
therewith. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement,
such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof
with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized by the Company in writing,
(y) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (z) in such action there
is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party
effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (2) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations,
warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action
or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Pre-Funded Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Shares and Pre-Funded Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Pre-Funded
Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Pre-Funded Warrant Shares, and will take such other action
as is necessary to cause all of the Shares and Pre-Funded Warrant Shares to be listed or quoted on such other Trading Market as promptly
as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a
Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules
of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until the one (1) year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that, after six (6) months following the
Closing Date, the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent
shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed
to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent,
including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Pre-Funded Warrants set forth the totality of the procedures
required of the Purchasers in order to exercise the Pre-Funded Warrants. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Pre-Funded Warrants. Without limiting the preceding sentences, no ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise form be required in order to exercise the Pre-Funded Warrants. The Company shall honor exercises of the Pre-Funded Warrants
and shall deliver Pre-Funded Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted
Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the
benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Pre-Funded Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any
such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for
such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Pre-Funded
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NanoVibronix,
    Inc. </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy to (which shall not constitute notice):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">NAOV</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Pre-Funded Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: _______________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
<FONT STYLE="font-size: 10pt">Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations
of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and
the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall
be disregarded, (ii) the Closing shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii) any condition
to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company
or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition
and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NanoVibronix Announces $2.4 Million Registered</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Direct Offering Priced At-the-Market Under Nasdaq
Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ELMSFORD, N.Y, November 29, 2022 &mdash; NanoVibronix,
Inc. (<U>NASDAQ: NAOV</U>) (the &ldquo;Company&rdquo;), a medical device company utilizing the Company&rsquo;s proprietary and patented
low intensity surface acoustic wave (SAW) technology, today announced that it has entered into a securities purchase agreement with several
institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 4,800,000
shares of its common stock (or pre-funded warrants in lieu of thereof) at a purchase price of $0.50 per share (or pre-funded warrant
in lieu thereof). The offering is expected to close on or about December 1, 2022, subject to satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The gross proceeds from the offering are expected
to be $2.4 million. The Company intends to use the net proceeds from the offering for general working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">H.C. Wainwright &amp; Co. is acting as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities described above are being offered and
sold by the Company in a registered direct offering pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-239965),
including a base prospectus previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which was declared effective
on August 11, 2020. The offering is being made only by means of a prospectus supplement that forms a part of the effective registration
statement. A final prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and
will be available on the SEC&rsquo;s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the
accompanying base prospectus may also be obtained, when available, from H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor,
New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About NanoVibronix, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device
company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization,
as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company&rsquo;s
primary products include PainShield&reg; and UroShield&reg;, which are portable devices suitable for administration at home without assistance
of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release contains &ldquo;forward-looking
statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo;
&ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo;
&ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential&rdquo; or similar words. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which
are beyond the Company&rsquo;s control, and cannot be predicted or quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance, are
based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s
control, and cannot be predicted or quantified, and include, among others, statements regarding the consummation of the registered direct
offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds
from the registered direct offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of
our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability
to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger,
multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance
on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our
products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative
or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for
certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given
the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in
foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications
challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions;
and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization
of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities and Exchange Commission (SEC), including
the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read
these documents free of charge on the SEC&rsquo;s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update
or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investor Relations Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Brett Maas, Managing Principal, Hayden IR, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">brett@haydenir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(646) 536-7331</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? ) # 2(  A$! Q$!_\0
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6CDGC%=A0 !T %%B77O'EMWZ]^Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>naov-20221129.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKIabP9z5Z8SekhvWBzbWnKLyAqE0pqTCc+ESHmgasP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:NAOV="http://nanovibronix.com/20221129" elementFormDefault="qualified" targetNamespace="http://nanovibronix.com/20221129">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanovibronix.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="naov-20221129_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="naov-20221129_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>naov-20221129_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>naov-20221129_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20221129.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140283875296496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 29,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NanoVibronix,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0801232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">525
Executive Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Elmsford<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">233-3004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value
    $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NAOV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not
Applicable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="naov-20221129.xsd" xlink:type="simple"/>
    <context id="From2022-11-29to2022-11-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-29to2022-11-29">0001326706</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-29to2022-11-29">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-29to2022-11-29">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-29to2022-11-29">2022-11-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-29to2022-11-29">NanoVibronix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-29to2022-11-29">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-29to2022-11-29">001-36445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-29to2022-11-29">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-29to2022-11-29">525 Executive Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-29to2022-11-29">Elmsford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-29to2022-11-29">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-29to2022-11-29">10523</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-29to2022-11-29">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-29to2022-11-29">233-3004</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="From2022-11-29to2022-11-29">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications contextRef="From2022-11-29to2022-11-29">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-29to2022-11-29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-29to2022-11-29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-29to2022-11-29">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-29to2022-11-29">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="From2022-11-29to2022-11-29">Common Stock, par value     $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-29to2022-11-29">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-29to2022-11-29">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:27%YO3D7H;G"-QE 7=Y#-P0AE*SF-S+B&_(9_Y6A8<K^9"S)NU<^!T$ZZK
MNCH&ZYEMR'T$;&(N0I9;^.$1Q15A0/U+/Z!-K,0"O[1,_QA & 6E4Z5SME,R
MM? *$*7)4&604,BKBBI'ND;]=H1![OEZ< SD((K #<WI^P9Y@.O(HZPFPR7;
MM'TRVO P<XV4W,2K"*O"H/3^ +7N'U"';@\2^:S6LA*S1BY.#$Q7(HRM]/T
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M[7QSR1F\R.X".#]7RK[ON.5V\;6D_R]02P,$%     @ US"!59^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
MUS"!520>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ US"!50=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #7,(%5&[&N
M)^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #7,(%5F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -<P@563TP)Y? 0  #D1
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #7,(%5GZ ;\+$"  #B#   #0              @ &_#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -<P@567BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
    <File>naov-20221129.xsd</File>
    <File>naov-20221129_lab.xml</File>
    <File>naov-20221129_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "naov-20221129_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "naov-20221129_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "naov-20221129.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 60,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "NAOV",
   "nsuri": "http://nanovibronix.com/20221129",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-11-29to2022-11-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nanovibronix.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-11-29to2022-11-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-22-034062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-034062-xbrl.zip
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MCX[PTL)?9@4O6#!!F"6VYEER%QU+MK* ^V5* # +JX5]5=E3CJ-JUNRVD[N
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MMP1,NAN)2"VAED;>+R+=ST G(I DLVNSHDZJL"("DLWN,K4,',[T8LD<K5V
M1 Q-O8<A94V4+5<5DF<P>I1&!/W(:@L"=2#8#CJNPRIS/WCY[B_'H"89/#M]
M>W9Z?OKZW<F[5V]>GQ/7X.\G9V<GK]^].CV_'Z._AP"51T(V>#;@$/A]DT.
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M2U!QF@V?>\V'9B4_W2:KI$;G.-'"2\AA\NP@Z&PW:VB* FJ>\QQEPTQ:@WM
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MTBT[PA>"N8F%$]@E4MUJ_G 2V0GO0P8"_ZVEK_6P-HN/V[H6KC TJ:1SY$N
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M*W8;O(\+.'=YJ)QP88N-$&PD2;9%,'#<4@]*WDT[U;Z6PL7$!. I2&U6NN+
M[5RA;,T( U6*\D+5G2J(<)& Y03+(*6!J>D\X2)#FGO*H)ZQM56C=IFS83U
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MX;^)O0&;7I@\991RGJPQQ4 J6F26B,E?VYGWT)"PSY.K#K,3^V7\#<[@(NX
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MQ](JR' 1F?EB7M*IR'$[HBYT?\;G"I&*Y9F9,[O,&&.'-I0NT(Z$!$LH$"6
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MJ@?^74V6^3I$,_6;Y%Y9$8==F;1%-B@A!(;/,<F+2KPQQ<LCVEX_EB'YC;,
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M#6ZU B1>[A/(RY68N<!P<J$;5$TB38?8QXW6:FL;U[&G:!N?BV3XF-'!L(*
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M]MFGQO1;O3V,W9P3$,B)-7A@2?<2:@GCNZR''^*=6:KX4>]51<(K >!)'BZ
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MA2/'QI;Q0D]5#)UHF>9E2:BP%S05IXD$16"#R)>T6@&E^SBV=0L\.DGL:A?
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MLVJ)('^X8D*ZIVDT*,5VEF-#2D*H^@K(,=4+TU5<RXJW0BZ3;DIU\ 7)\B1
M.>C\;4%_8B--E8X_!LUQ5/FI>B^QJX_*'L(-"&F7+O*K^)([;8:!*E @$7:I
M4R0:\C(X(]?,-I+9F#2CYOF';J3HBFI2=21)@C!UFQH]?DA#*P&Q3\CS)*7>
M4%L6:N1B^K*X_6!<-Y:/W0^$ZW9$YV8H)=,>%!_$%ZH"#YUP!2)[/H7_3<"6
M2,2-";;/= @J>XPVB^),FR%M-I07.XDKJK\DB>,T]3VE5#:HC0.J;042/QH3
M9F@^BLM2@$);H/^I%@5>2^^1<V2RF ,GB;G;H5+2C/<4+$,PQY(2*3Q*XXC@
M)>V>GV)-D3TLQ:>ZIK37,F>ZA;"AZ.B:N.!&^-^395VJP-E>FBM>W,WSCV6]
M#H""4NA>8TQ+U$I*-(XE^W*(O^*D<FZD09K&0K*\10*#=H9BJM0A9C[SS;I7
MN+&F'\*R;@#K^=/&/%^K>?[3QCQ_0$?X[DKC8BX&]-S"6DMY9PIWVLK'\-Z0
MG%/\L W4C\-*D>M<IY".)$. VJ><T5:$9.&&E-JN$!UD=D*UH;I=@(1:A>9@
ML<0B9.+*3E9&!Y@'])3=9L\T7<Y7Z"7GU$!L5?EY3+J;CNMY!.^#ZIIB.*,,
M=4,G6D:W<QP7)0:%T(+GO.<HP()I-,^;WQJ(MMM<6V>&DN(0&<!.ANY759$,
M&0S]F NI[5@P)K@K4,<L1J6;^L7E5^2$P)!JJ7/ =O43P=$5J OE13*SV,K!
MR*>^?3T.>NFJ$(T;5,3GN1WC"9EKKHO:U>;8:(.@SF-1!C]J((+..,,81VP%
M#4G#:1G?0;UL/1\M)2R<U"#8*DRQ1)5^<Q-0F*%,"PB/T^(@U+5DX?<W8W-2
M-9@?%.$,>XKL9'EFTA=;#FBW<RWA#9]ZY(<OFJBO.W":J15H'L*=7%I1Y[DU
M.6S> +/EARIWMB;89;HK>#$W*^M Q[,")YREW^$0=Z"#W6!Q2?T)-X*S?AUP
M3;V>O2UOLBC-S_.Y-@VM7YD&0!+ANQF=NYUK"8TM:A$SQQ5[B6K2X =;0]69
MS3JPP <F\0=+]\PD:8HD!Y2)/<0:J'2$W3#$A]$"R_#D&6(6R1;!'"^B#'2,
M_JC2?H1BG@JC%+J]1NGTUJBL &92\5$">6]@(GSJU3(Z!&#*\4C[V02J'Y):
MEQQ<2O/ A("6M>F"W<;%F9PF4'_1P$)Q >O3Y;ET*Z/KA:A@A[N'F):4UJA+
MQ,!IP,UN7Y62ZM#*>4E6WV.%X2;H:X[,(D==+"XI&[Q7IT.0[-DB/Z"0"Y/9
MZL>S@;W=>Q!I<+TD[W$1L?(?ML@P;WX6O\IAP'T(QDDY*N*F'!FU<=3YN%0R
MJK&,SD]:D4+[^OWM$);XY3,HVR#WOI"PH*A\ 66I^(\*UR2?1U?LK:!#A+X7
M4>T3J999;N>6P!LO415>R-5!N7JDS8V %-%HH?W-#IV=)$Q.8K#9.]*1)-;,
M,"$*>[5%)9V9&$X\R1[.?;2V6F.FW:[0(Y7 R2FZ1EHGF9Y<O6.J76+7K%R$
M1M%'3WB!LHHZH=[P/9R ,3&0<8*=4,O[L.'PN HO&?&UEV$<C&'O6 ):R75[
M.GLPY'I"J<5E[WU(J @1O)M  ?C=<V"E$;XVG\-&D0/:#2T0FL*>_SLO8TAA
M9EB_J>K)N%A92-%.NGY74NHLDFYS*C'^3(V.ME%!Y*A7DS35Z"YI3ZN.#KXO
ME49%&0W4=!NNEEOGPOCQD8.YF.;.-V*=IE/68OO1QFM%C")53K);FW88FFPG
MSS:MZ5^K*;AEHG+7,(^9Y(<6I!QHN@D%KBQ 4;;<K03?Y2+5@9#5E'R^_?//
M?U8T:-I1=:B:^-%I*;9D(YS G[>P;N<F)I6=S2>9=7+^?!S(*>4O4W%VS#FB
M\O>VVZ?;L4S8AA;)KC1UD0)6L8J3C'J%4N!/4I2#G^O4]\S.VR9_2\H<GET;
M:"%.VZ)\UU!* 1+EJ%//:9M0IUQL!_W,VB#1O:[=%QW6&,86R(YI5__3DU>G
M'XY?E]6KQ_@G=1>T2@E4=N>RCNUGC8OJ=G2+;".&8%5E5<REXUB"&;UX?:B@
MK0133'J)0HB 'R6P/2AP,:A7+=H:8CB4I-S>HF"STVG:S;"TEF.-@RX]$3,J
M<ATK>E&8&R>/H#C*3T&<@M8?<O5US,QFJMVY-J?TZRDBS+$ZPXD^\YD0!0RL
M&)U(6 5/Q[%,"I6""N2&&S[EAM^^ \\8*[PW-O"0'E[P?QRB\#81MS'2!>'R
MEB6,;C!(OD8!X0-%2;L-2->_;F)*:XTI_?7[C"D]U!-W-R'A#Z]UG>PS#AEA
M"@(P..*^]'4^8WFK2),/<#?OC$DCCA"RZK>?4 G*F+T-I[,T::[#INQ6506%
MFD4:U]P_EG+*+:IG!#?'J2?<ICW.QDY K]M!G0$?&B-0HC*?4$6P_EU2NU6M
MNZ+IY6K%A>6VE[*57/_-JE.S##]5RY.H-]<K2;9(@9+.&)=Y,E9J]#B?#ZO0
M"GFJ^)%8VFU!H]A/6VPV=S3TE@+(*^=#IEZYBI4(:AR%)3"ALZA9=:$ XXWR
MZ1!TI](IP\3BQ@6#LZ'MC/Y1-KV1+WHW&+R<(NY#T^C41_BRQ_0@X$K0:=.H
M+!G50CR+C@G4[;@N)(?(HVB68,8?3]0WY\D'X7@BJWJ&M,F(U<G4U/+ R2(G
M7M .K[B(JMS"PEO)E[/%\3QR+J#A,R\6FBRJU+7-P),":LY"OR2'ON.590]]
MEI,'\\8S6VY6FD&-8U:_DKP)5#R^6E349/&"VL\&BXRE6FS2<-JP;L7=JT4G
M^<T<U 2CD.V0,9N:5MX]I3V[V6J6K84XX7J.A%IH#,TZ93B*2CB&5*<^H=;R
M3<$2*_VN=*H,! M07-26C'0$(B4WWV!6W8YY@&960R84F<*^4A8&D9*]1?S(
M/9(;V^B>+&LH=_M\6)*V7PFT2G $[(!YQ64K H4Y(HTH*7PR*-[!TLI2!^P;
M[9SPDT+$PB4!GU.+F+2DI]M"ZL1T/%&[\*;DT,.5@#*%CN-6%1^P^Z"B+&WL
M!!HIGPX?S&Y'G3I)$"#.7B:E*\>O>JPF8S!J&A 4;# 8KXPH&G'N>[>C2YC8
MS6.E&REOAS=8Z$E [^MZ1=/(5+++L&,%&2)/7$1($73HK70Q\%N,6*=8-\BV
M=OF^I9(J<,[%6'&7[;>QK@<N:LXGMN.]*2MC!1=KK^F^5)YWT[XK4@(;,9-!
M]\R,T#YG5[]QF!9<[*X"B+7=R1F1)9/=\UX<FM%MM[]U9UB<V::#FH(0*^JA
M\#"L"5\[VV#+KU$)&DM4^/!@+U^38=<0M#9UY@K>DR\94L[JPTM:$BP15"QU
M&0E+LCM<126O<P+7#YU1P_T"/G=J3=,R"+*TVBV"JJGGM2BB:F6G(:P9J=4U
M;X W% ?55YB2UI?HT"*%A_&"4QH5&P@=++17E,K$FKBY% I%FTGV3(IX>$<X
M[^6S=L4^>]^,@B#C/XS;_($J*2-64H[AOC[!^WK?-O59/]F?4Q&49N8:.K#K
M;J@!8_&I&:-E64@# VE^HU7L+4G'I; ,%N?VC$[A.B/8XP!:0XQBU%%5Y):U
M'J!(34VPU_,I;%N[FA><^*.,6=M%LE+&HC_A4OE%_+2@T.A+^.V,;V0]&4P?
M4!0"=6N&R0*325BST4,+[AU,6=R3<PKTA)2NQJ6)UL?65*2 S4+CZKE0538[
M..H6X1=II=-88&[_##MJCU>%R422_+TV//OKK@Y[7I3Z28E@6(;9?%?:N$+6
M^R1A$7L@^II9\#F*F>B5Z];,@L]1S+J=S]#,)LLTLSKI5U*[N.?HRGI7G;S+
MU"ZSF1+9K\VQKFRU% 0WE#-\CK+EC+V*JL4*[[5I>%^D:CF3:E"T$LD?:U.X
MECA3F]2M)</U3+Z"25YL.-.MNI;>>IZKU^5HO9H7JM[W4O7:J#UK*Z[\VR80
MOM9 ^-\V@?#-$5Y?I\4W\VP<31EIXLSHL2IN>L-8:<BMNNRP%<.,I O.U5+_
M(DT6<W?1827)R)R&;BG3I80&V.$ZC2D(R*GQ) 5T1,(VER@%C,8BI9 U=2XC
ME!"DE]R,?Z"3.0&MKD#TE;89VY-!]U0()YXT\#09(:P+7I$*;"34<!XA9^\N
ME!M.6V6Z=2GJ!X2*BH$,I&1%U5("'.]8;)IH&/6 C8VE#WN=="HV:NV!O9[0
M K><T"PK!=(_82+'DLR/QAQ^M*4J.>HIY2Z5J2V44N%=:$+67BV5M::H2CM!
MUL30V:XF)HG/4F  PR4*-I$4FKIM2!A5N>531[U)]]GBONLFB&W-Z<>=/Y.5
MG9M.]1:'>P%<>+#A^<N<,LUGH"-K,.01_TR%]+W@+L61;W!NB!RKG9NZO0O&
M4'$>9<F_K2B9F.OZLZ:$73XKN+7SM,Q5Q)>4/-Z6^E[77I*4)MY'"+2J]I'.
MJ[7'XQ7WE</PESVG:&$%L;.$>BA?YM,I5Q(9_P-#K^ES0[VC7(? <%YB'D*)
MZ:0F"GFMT\/;D+"V'>R^>$3N"R,&&[T3/54/Y51HX^-<_0-/JZ+M*]3A54<^
M^P2;I\4G5%YS*%IC\>ITB(S_S.,1;)'/PW:L++FVW)"6Y-:S>:DBB<BR;4@
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M@JQT2:#E5_38^-/\*+UQKB[R5+#8R5L3*J-%^G77\G[8YD"#!_M<S\A5-=%
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M(D2[G8N("I1<?N3\F[N_M#=7]NJXHX=F_W1[88OQ5"N2A-U,Y$DB%&I)!><
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MIY#N)';\"HZ[VJC]"JI OF;\,^T(RPD76][#?@.3KWI!Z7Z4C*EQ>VJ6:-B
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M@0H$"H0S9F&/8HU:BH&+8@:LUARJ-'V@X$(M,BS&&O*=) .(!U%>VUB>1<Z
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M@GI(+H4R:FVXQ,=%,S7Z)VPG=,I5F+GJJ!0@;43\QN#D)M:0DGM$!G3"Y52
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M2A@CSAYS!+]%DHO+^P? F:D=,HO>@:9XG>PHUPMZ71 .)I<@7\'@<@U369+
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M$9*%U"Z$Y!%!^G0N)SYZE#]> 6NL9N!E_H WH/.7'*&P]O;-LFMON[66QX;
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MUY:X8@,RIYDPRX-@ 3!E,J!D2.J0$GKI>7V7@.;R(4:P.:;,+0%VDTT*FIJ
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M+3$N:'1M4$L! A0#%     @ US"!5;,&[/GO"@  C3\   D
M ( !E]\  &5X-2TQ+FAT;5!+ 0(4 Q0    ( -<P@54*_<;E7 T  $4L   *
M              "  :WJ  !E>#DY+3$N:'1M4$L! A0#%     @ US"!53$/
M][3T%P  Z;D   L              ( !,?@  &9O<FTX+6LN:'1M4$L! A0#
M%     @ US"!50.Z#+Q4 P  Q0P  !$              ( !3A ! &YA;W8M
M,C R,C$Q,CDN>'-D4$L! A0#%     @ US"!56%V70@X"P  )XD  !4
M         ( !T1,! &YA;W8M,C R,C$Q,CE?;&%B+GAM;%!+ 0(4 Q0    (
M -<P@57AP*/0> <  (U9   5              "  3P? 0!N86]V+3(P,C(Q
A,3(Y7W!R92YX;6Q02P4&      @ " #< 0  YR8!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
